Post a Comment Print Share on Facebook

Bayer goes against the first glyphosate-judgment in appeal

The pharmaceutical company Bayer against the judgment, the glyphosate-wave of lawsuits triggered, in appeal. The group denies that the agent is a carcinogen, an

- 4 reads.

Bayer goes against the first glyphosate-judgment in appeal
The pharmaceutical company Bayer against the judgment, the glyphosate-wave of lawsuits triggered, in appeal. The group denies that the agent is a carcinogen, and refers to appropriate scientific studies. This Thursday, Bayer submits its quarterly numbers. the

The agricultural chemical and pharmaceutical group Bayer goes against the first judgment of the glyphosate-action shaft in the appeal. The company's subsidiary, Monsanto had requested that the verdict of the jury in the case of Johnson cancel and dismiss the action, said Bayer. The evidence presented in the case would prove, by Far, not the responsibility of the company. Bayer also pointed to "the consistently positive assessments by international regulatory authorities and the assessments underlying a substantial body of scientific evidence that glyphosate is not carcinogenic".

In August of last year, was awarded to a sworn jury to the cancer patients Dewayne Johnson a total of 289 million dollars in Pain and suffering, and compensation. The judge lowered the penalty against the U.S. Seed company Monsanto later at about 78 million dollars (69 million euros) - you power of glyphosate, however, still for the cancer of the man responsible. Johnson had used as a former groundsman at a California school, over the years, glyphosate-containing products, and the company accused of being to lymph glands cancer. The judgement had brought the wave of lawsuits against Bayer, only to roles.

Bayer rejects the accusations of a cancer risk to back

On the stock exchange, the group is because of the many glyphosate-action lawsuits in the United States now under massive pressure. Investors and analysts question whether the Leverkusen may have underestimated the risks of some 63 billion dollars (56 billion euros) expensive Monsanto purchase. Meanwhile, Monsanto in the United States were glyphosate-related lawsuits from more than 11,000 applicants.

Until the end of March had lost Bayer a further important process to suspected cancer-causing products of the subsidiary Monsanto: The group must pay to the 70-year-old plaintiff Edwin Hardeman damages in the total amount of 80.3 million dollars (71.4 million euros). It was a pioneering Bellwether Case: a kind of pattern case in US law in a mass procedure meant. Several of these representative cases are reported. They should help the parties to the dispute, to the extent of damage and the amount of possible payments of compensation in a better estimate.

glyphosate is one of the world's most widely-used weed killers and was developed by the U.S. seed giant Monsanto, Bayer in the summer for around 63 billion dollars. Bayer rejects the accusations to the risk of cancer, and refers to numerous studies. The Dax-the group stresses to be optimistic: so Far, the company saw no reason to provide for possible compensation payments Provision. A lot of money costs, the glyphosate-sue but, nevertheless, already: The provisions for legal disputes increased in the last year of around 660 million Euro. This Thursday, the group shall submit its quarterly numbers.

Avatar
Your Name
Post a Comment
Characters Left:
Your comment has been forwarded to the administrator for approval.×
Warning! Will constitute a criminal offense, illegal, threatening, offensive, insulting and swearing, derogatory, defamatory, vulgar, pornographic, indecent, personality rights, damaging or similar nature in the nature of all kinds of financial content, legal, criminal and administrative responsibility for the content of the sender member / members are belong.